Abeona Therapeutics

abeonatherapeutics.com

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s Zevaskyn™ (Prademagene Zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB). Abeona’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for Zevaskyn commercial production. The company’s development portfolio features Adeno-Associated Virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.